Literature DB >> 30612711

Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma.

Stephen M Ansell1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30612711     DOI： 10.1016/S2352-3026(18)30210-2

Source DB:  PubMed          Journal:  Lancet Haematol        ISSN： 2352-3026            Impact factor:   18.959


× No keyword cloud information.
  4 in total

1.  Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4).

Authors:  Rong Tao; Lei Fan; Yongping Song; Yu Hu; Wei Zhang; Yafei Wang; Wei Xu; Jianyong Li
Journal:  Signal Transduct Target Ther       Date:  2021-10-27

2.  Durable Response to Immunotherapy With Antiangiogenic Drug in Large-Cell Lung Carcinoma With Multiple Fulminant Postoperative Metastases: A Case Report.

Authors:  Zhilin Luo; Hong Zhang; Yajie Xiao; Rui Wang; Liping Zhang; Chenglu Huang; Yu Cao; Chao Sun; Yongtian Zhao; Hanqing Lin; Dongfang Wu; Tianhu Wang
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

3.  A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report.

Authors:  Jianzheng Wang; Qingli Li; Huifang Lv; Caiyun Nie; Beibei Chen; Weifeng Xu; Tiejun Yang; Yinping Zhang; Shuiping Tu; Xiaobing Chen
Journal:  Front Oncol       Date:  2021-06-18       Impact factor: 6.244

4.  Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer: A case report.

Authors:  Lin Zhang; Wuqian Mai; Bo Hao; Wenyang Jiang; Qing Geng
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.